Silo Pharma Inc (SILO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Silo Pharma Inc (SILO) has a cash flow conversion efficiency ratio of -0.160x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-781.86K) by net assets ($4.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Silo Pharma Inc (SILO) market capitalisation for the company's overall valuation and market capitalisation.
Silo Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Silo Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Silo Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Silo Pharma Inc ranked by their cash flow conversion efficiency. Explore SILO operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cerebra Integrated Technologies Limited
NSE:CEREBRAINT
|
0.024x |
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
-0.181x |
|
Madhav Marbles and Granites Limited
NSE:MADHAV
|
-0.005x |
|
Crown Capital Partners Inc
TO:CRWN
|
0.270x |
|
Vaxtex Cotfab Limited
NSE:VCL
|
-0.091x |
|
Australian Silica Quartz Group Ltd
AU:ASQ
|
-0.107x |
|
NIOX Group PLC
LSE:NIOX
|
0.130x |
|
Mustang Bio Inc
NASDAQ:MBIO
|
-0.128x |
Annual Cash Flow Conversion Efficiency for Silo Pharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Silo Pharma Inc from 2011 to 2025. View today's stock price for Silo Pharma Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.31 Million | $-4.66 Million | -0.739x | +2.93% |
| 2024-12-31 | $5.03 Million | $-3.83 Million | -0.762x | -45.89% |
| 2023-12-31 | $6.18 Million | $-3.22 Million | -0.522x | -54.34% |
| 2022-12-31 | $10.34 Million | $-3.50 Million | -0.338x | -34.55% |
| 2021-12-31 | $9.06 Million | $-2.28 Million | -0.251x | +72.18% |
| 2020-12-31 | $1.28 Million | $-1.16 Million | -0.903x | -102.60% |
| 2019-12-31 | $-22.89K | $-794.32K | 34.699x | +5085.55% |
| 2018-12-31 | $407.44K | $272.64K | 0.669x | +382.84% |
| 2017-12-31 | $1.20 Million | $-284.62K | -0.237x | -39.51% |
| 2016-12-31 | $846.51K | $-143.56K | -0.170x | +67.32% |
| 2015-12-31 | $1.96 Million | $-1.02 Million | -0.519x | -15.64% |
| 2014-12-31 | $2.37 Million | $-1.06 Million | -0.449x | -341.92% |
| 2013-12-31 | $1.79 Million | $-181.61K | -0.102x | -119.48% |
| 2012-12-31 | $-41.19K | $-21.47K | 0.521x | -98.03% |
| 2011-12-31 | $-1.75K | $-46.30K | 26.489x | -- |
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's… Read more